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Abstract 
Hypochlorous acid (HOCl), an oxidant produced by myeloperoxidase (MPO), induces protein 
and lipid oxidation, which is implicated in the pathogenesis of atherosclerosis. Individuals 
with mildly elevated bilirubin concentrations (i.e. Gilbert’s syndrome; GS) are protected from 
atherosclerosis, cardiovascular disease (CVD) and related-mortality. We aimed to investigate 
. 
 
whether exogenous/endogenous unconjugated bilirubin (UCB), at physiological 
concentrations, can protect proteins/lipids from oxidation induced by reagent and 
enzymatically generated HOCl. Serum/plasma samples supplemented with exogenous UCB 
(≤250 µM) were assessed for their susceptibility to HOCl and MPO/H2O2/Cl- oxidation, by 
measuring chloramine, protein carbonyl and malondialdehyde (MDA) formation. 
Serum/plasma samples from hyperbilirubinemic Gunn rats and humans with GS were also 
exposed to MPO/H2O2/Cl- to; 1) validate in vitro data and 2) determine the relevance of 
endogenously elevated UCB in preventing protein and lipid oxidation. Exogenous UCB dose-
dependently (P<0.05) inhibited HOCl and MPO/H2O2/Cl- induced chloramine formation. 
Albumin-bound UCB efficiently and specifically (3.9-125 µM; P<0.05) scavenged taurine-, 
glycine- and N-α-acetyl-lysine- chloramines. These results were translated into Gunn rat and 
GS serum/plasma which showed significantly (P<0.01) reduced chloramine formation after 
MPO-induced oxidation. Protein carbonyl and MDA formation were also reduced after MPO 
oxidation in plasma supplemented with UCB (P<0.05; 25 µM and 50 µM, respectively). 
Significant inhibition of protein and lipid oxidation was demonstrated within the 
physiological range of UCB, providing a hypothetical link to protection from atherosclerosis 
in hyperbilirubinaemic individuals. These data demonstrate a novel and physiologically 
relevant mechanism whereby UCB could inhibit protein and lipid modification, by quenching 
chloramines, induced by MPO-induced HOCl. 
KEYWORDS: Bile pigments, heme oxygenase, antioxidants, protein oxidation, 
myeloperoxidase, chloramines
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1. Introduction 
Unconjugated bilirubin (UCB), a potentially toxic by-product of haem catabolism, 
also possesses powerful antioxidant properties. Epidemiological studies report that 
individuals with elevated UCB are protected from the development of intimal hyperplasia, 
atherosclerosis and cardiovascular disease (CVD) [1-7]. Furthermore, higher UCB 
concentrations (in the absence of haemolytic or liver disease) are associated with reduced 
incidence of CVD-related mortality [8-12]. The mechanisms responsible for CVD protection 
are not clear, however may be related to the potent antioxidant properties of UCB, given the 
potential role of oxidation in the development and progression of atherosclerosis [13]. 
Numerous in vitro reports demonstrate the radical scavenging activity of various bilirubin 
species, which protect proteins and lipids from oxidation. Current evidence indicates that 
UCB efficiently inhibits amino acid oxidation mediated by hydroxyl, hydroperoxyl and 
superoxide radicals generated by radiolysis [14] and irradiation [15]. Furthermore, UCB is a 
potent lipid chain-breaking antioxidant scavenging artificially generated peroxyl radicals 
(2,2'-Azobis(2-amidinopropane) dihydrochloride (AAPH) [16] and 2,2'-azobis(2,4-
dimethylvaleronitrile) (AMVN) [17] and inhibits copper (Cu2+) induced lipid oxidation [18].  
 
Whether, bilirubin and related compounds protect from oxidation mediated by 
biologically relevant myeloperoxidase (MPO) and hypochlorous acid (HOCl) [19], remains 
underexplored. This is an important phenomenon to investigate, because MPO is strongly 
linked to the development of atherosclerosis [20-23]. Evidence to support a role of MPO in 
the pathogenesis of atherosclerosis includes the deposition of MPO in atherosclerotic lesions 
[24,25], the extent of which is inversely related to plaque progression [26]. Myeloperoxidase 
generates HOCl, a potent oxidant, which reacts with most biological molecules and targets 
proteins for oxidation [27]. Reaction of HOCl with amine groups on proteins gives rise to 
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chloramines, which decompose to form protein carbonyls [28,29] and can also induce the 
oxidation of low-density lipoprotein (LDL), which may be important in the development of 
atherosclerosis [30]. 
 
Some controversy exists regarding the role of bilirubin and related compounds in 
scavenging MPO-derived oxidants. Bilirubin ditaurate (BRT; a synthetic water soluble form 
of UCB) and biliverdin (product of oxidised UCB) inhibit MPO-mediated 
chemiluminescence [31] but fail to protect guaiacol from MPO oxidation [19]. However, both 
compounds prevent human polymorphonuclear leukocyte α1-antiprotease inactivation and 
tissue proteolytic attack by reagent HOCl [19]. Interestingly, preliminary in vitro data 
indicate that albumin-bound UCB does not react readily with HOCl [31]. This result is 
surprising when considering that persons with Gilbert’s syndrome (GS) [32] who possess 
mildly elevated UCB concentrations (> 17.1 µM), demonstrate reduced protein carbonyl 
concentrations [33]. Given that the decomposition of intermediate chloramines is a pathway 
responsible for the formation of protein carbonyls, these observations support a potential role 
for UCB in the inhibition of MPO activity, and / or the scavenging of HOCl, or chloramines. 
Whether higher, physiologically relevant, UCB concentrations scavenge HOCl or prevent 
protein oxidation (e.g. chloramine/protein carbonyl formation) in plasma samples remains 
unpublished. 
 
Therefore, the aim of this study was to investigate whether serum/plasma samples 
with exogenous UCB supplementation or endogenously elevated UCB in serum/plasma from 
unique models of benign hyperbilirubinemia (Gunn rat and human GS) protect from protein 
and lipid oxidation induced by reagent and enzymatically-generated HOCl. We hypothesised 
that bilirubin would protect from protein oxidation, by quenching HOCl-induced chloramine 
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formation. These data may help to rationalise the association between bilirubin and protection 
from CVD. 
 
2. Methods 
2.1 Human subjects 
Forty-two subjects (21 GS; 21 controls) were recruited and matched for gender, age, and 
body mass index (BMI). Equal numbers of female and male subjects existed in each group 
(11:11). A female control subject with normal UCB concentrations (10.3 µM) was used as a 
quality control for in vitro experimentation (ie. exogenous UCB supplementation for HOCl 
and MPO oxidation). Fasting human blood was collected in serum and 
ethylenediaminetetraacetic acid (EDTA) vacutainers. The recruitment of human subjects 
received ethical approval (MSC/02/10/HREC) from the Griffith University Human Research 
Ethics Committee prior to experimentation commencing. 
 
2.2 Animals 
Breeding pairs of heterozygote (genotyped) Gunn rats were imported from the Rat Research 
and Resource Center (Columbia, MO, USA) and kept within an animal housing facility at 
Griffith University (12-h light:dark cycle, constant temperature (22 °C) and humidity (60%)). 
Rats had continuous access to standard laboratory food pellets (Speciality Feeds, Glen Forrest, 
Australia) and fresh water. Female homozygous Gunn rat offspring were assumed to possess 
jaundice at birth, were ear-tagged, and housed together with female littermate (non-jaundiced) 
controls after weaning. Gunn rats (n=9) and littermate controls (n=5) at 12 months of age 
were anesthetized using intraperitoneal injection of pentobarbital sodium (concentration 
60 mg/mL; 100 µL/100 g). A midline laparotomy was performed, and approximately 5 mL of 
whole blood was collected from the thoracic cavity using a syringe and was transferred into 
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serum vacutainers and prepared for analysis (see section 2.3). All procedures were approved 
by the Griffith University Animal Ethics Research Committee prior to experimentation 
commencing (MSC/06/12). 
 
2.3 Sample preparation 
Whole blood was centrifuged (Thermo Scientific 5810R, Australia) at 2500 x g for 10 min 
(4 °C). Serum/plasma aliquots were prepared immediately and stored at −80 °C until analysis. 
Human serum samples were used for biochemistry, antioxidant activities and HOCl 
oxidation, whereas EDTA plasma samples were used for MPO oxidation, measurement of 
chloramine, protein carbonyl and malondialdehyde (MDA) concentrations. Serum samples 
obtained from animals were used to perform all analyses. All reagents used were of analytical 
reagent grade or better and obtained from Sigma-Aldrich (Australia) unless otherwise indicated. 
 
2.4 Serum biochemistry 
Serum samples from animals were diluted 1:1 with distilled water and analysed for the 
activity of liver enzymes (alanine aminotransferase, aspartate aminotransferase, γ-
glutamyltransferase), glucose, uric acid and lipid parameters including total cholesterol, 
triglycerides and high-density lipoprotein using commercially available kits on a COBAS 
Integra 400 blood chemistry analyser (Roche Diagnostics, Australia). Cholesterol analyses 
were conducted using appropriate lipid standards (Calibrator for Automated Systems Lipids) 
and quality controls (Precinorm Control Clin Chem Multi 1 and 2; Roche Diagnostics, 
Australia). Total non-thiol antioxidant capacity including ferric reducing ability of plasma 
(FRAP) [34] was also assessed on an open channel of the COBAS Integra analyser. All 
analyses were conducted in duplicate.  
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2.5 Determination of bilirubin concentrations 
Serum UCB concentrations were quantified using high-performance liquid chromatography 
(HPLC) and a photodiode array detector (Waters, Australia) as previously described [35]. A 
slight variation to this method included the use of C18 reserve-phase HPLC guard and 
analytical column (4.6 mm x 150 mm, 3 µm; Phenomenex, Australia) that was perfused at 1 
ml/min. Extracted samples were injected (100 µL) with a run time 15 min in duplicate. 
Unconjugated bilirubin (Frontier Scientific, USA; 0-100 µM) served as an external standard 
and was detected at 450 nm.  
 
2.6 Induction of hypochlorous acid (HOCl) oxidation  
Human quality control samples (serum) were thawed to room temperature and centrifuged at 
2500 x g for 5 min and diluted (1:10 for reagent HOCl oxidation) with deionised water. 
Sodium phosphate buffer (0.1 M, pH 7.4) was prepared and treated with chelex resin prior to 
use, to minimise contamination with transition metal ions [36]. Buffer was stored at room 
temperature and used as a control in oxidation assays. Unconjugated bilirubin stock solutions 
were prepared fresh in 0.05 M sodium hydroxide (NaOH). Bilirubin solutions were protected 
from light using foil covered containers and used immediately. A final UCB concentration 
(1.56-25 µM; 5 µL) or NaOH as control (0.05 M; 5 µL) were added to diluted serum samples 
in new reaction tubes. Hydrochloric acid (HCl; 0.05 M; 5 µL; Ajax Finechem, Australia) was 
then added to the serum mixture to neutralise NaOH. Hypochlorous acid stock (1 mM) was 
prepared fresh in sodium phosphate buffer and 20 µL was added to the serum mixture (final 
HOCl concentration of 100 µM) and incubated in the dark at room temperature for 5 min. 
The serum mixture was transferred to 96-well plate which was then analysed for chloramine 
formation (see section 2.11). 
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2.7 Reaction of unconjugated bilirubin with biologically relevant chloramine species 
For in vitro experiments, which aimed to determine whether exogenous UCB could directly 
quench physiologically-relevant chloramines, UCB was associated with bovine serum 
albumin (BSA) to facilitate its aqueous solubility and to ensure that bilirubin was present in a 
biologically relevant form. Taurine- glycine- and N-α-acetyl-lysine chloramines (250 µM) 
were formed by the addition of HOCl to each amine in a 1:9 HOCl:amino acid molar ratio for 
5 mins prior to the addition of BSA (250 µM) in the presence and absence of varying 
amounts of UCB (0 – 125 µM). UCB was added to BSA as a concentrated stock solution (10 
mM) prepared in NaOH (0.05 M). Samples were incubated at 21 °C for 5 min prior to 
chloramine quantification (described below). 
 
2.8 Induction of myeloperoxidase/hydrogen peroxide (MPO/H2O2) oxidation 
Protein oxidation induced by MPO (PLANTA Natural Products, Austria) was conducted 
according to the method of Summers et al. [37]. Ten microliters of 2 µM MPO (final 
concentration of 100 nM) and phosphate buffer saline (PBS; 40 µL; Invitrogen, Australia) 
were added to human EDTA plasma (50 µL) in the presence of exogenous UCB (final 
concentration 0.78-25 µM; 25 µL) or NaOH as a control (0.05 M; 25 µL) containing HCl 
(0.05 M; 25 µL) to neutralise NaOH. Hydrogen peroxide (50 µL; final concentration 50 µM 
for chloramine analysis and 100 µM for protein carbonyl and MDA detection) was added to 
the mixture and incubated at 37ºC for 30 min for chloramine and four hours for protein 
carbonyl/MDA analysis respectively. Fifty microliters of human EDTA plasma and animal 
serum were added to similar MPO oxidation system with PBS (90 µL) for ex vivo 
experimentation (i.e. chloramine analysis). Catalase (100 µg/mL; 25-200 units) was added to 
quench any remaining MPO activity upon completion of the reaction. Sample oxidation was 
subsequently analysed by measuring chloramine, protein carbonyl and MDA concentrations.  
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2.9 Measurement of protein concentrations 
Human and animal serum protein concentrations were determined according to the 
bicinchoninic acid protein assay kit (Thermo Scientific, Australia). The samples were read at 
540 nm using a 96-well plate reader (Thermo Scientific, Multiskan FC, Australia). The assay 
was performed in triplicate and results expressed in mg/mL of protein. The co-efficient of 
variation for this method was 3.4%. 
 
2.10 Measurement of reduced thiol concentrations 
Reduced thiol concentrations were quantified with 5,5-dithiobis(2-nitrobenzoic acid) (DTNB) 
reagent. Reduced thiols react with DTNB to generate 5-thio-2- nitrobenzoic acid (TNB), 
which was quantified in triplicate at 415 nm using a 96-well plate reader (Multiskan FC, 
Thermo Scientific, Australia) according to the method of Hawkins et al. [36]. Reduced 
glutathione (0–0.5 mM) served as an external standard. Thiol concentrations were expressed 
initially in µM and then converted to nmol/mg of protein. The co-efficient of variation for 
this method was 2.6%. 
  
2.11 Measurement of chloramine concentrations  
Chloramine is a stable product of protein oxidation and was quantified according to 
previously published protocols [38]. After HOCl and MPO oxidation, 150 µL of the 
developing reagent (2 mM 3,3′,5,5′-Tetramethylbenzidine in 400 mM acetate buffer, pH 5.4, 
containing 10% dimethylformamide [Merck, Australia] and 100 µM sodium iodide) was 
added to 96-well plate wells containing 50 µL of sample mixtures. Serum/plasma and BSA 
samples were incubated on a plate shaker at 50 rpm for 25 and 5 min, respectively. The plate 
was read at 620 nm using a 96-well plate reader. Samples were assayed 3-5 times within ex 
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vivo and in vitro MPO and HOCl oxidation experiments. Results were expressed in nmols/mg 
of protein. The co-efficient of variation for this method was 5.6%. 
 
2.12 Measurement of protein carbonyl concentrations 
Detection of protein carbonyl with 2,4-dinitrophenylhydrazine was performed using enzyme-
linked immunosorbent assay (ELISA; Sapphire Biosciences, Australia) with the above-
mentioned 96-well plate reader. Each sample was assayed in triplicate, with experiments 
repeated five times and results expressed in nmols/mg of protein. The co-efficient of variation 
for this assay was 6.8%. 
 
2.13 Measurement of plasma malondialdehyde concentrations 
Malondialdehyde in human EDTA plasma was quantified in triplicate using HPLC via a 
modified method of Londero et al. [39], performed with a Hitachi Model F-1050 
fluorescence spectrophotometer detector set at 532 nm excitation and 563 nm emission and a 
HPLC column (125 mm x  4mm, 5 µm; Merck, Austria). The extracted sample was injected 
(20 µL) with a retention time of 4 min with a flow rate of 1.3 mL/min. 1,1,3,3-
Tetraethoxypropane (Sigma-Aldrich, Austria) ranging from 0-8.12 µM served as an external 
standard and the co-efficient of variation for this method was 8.8%. 
 
2.14 Statistical analysis 
SigmaPlot software (version 11.0) was used to analyse all data. Two-tailed, unpaired t tests 
(Student's t test or Mann–Whitney rank sum test) tested for significant differences in 
variables between GS individuals or Gunn rats and controls. One way analysis of variance 
(ANOVA) followed by Dunn’s post-hoc analysis tested the dose effect of UCB on oxidized 
product formation. Group data are presented as a mean±standard deviation. Pearson 
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correlation tested the relationship between UCB and oxidation products. The level of 
significance was set at P<0.05. 
 
3. Results 
3.1 Inhibition of chloramine formation by HOCl and MPO mediated oxidation 
Hypochlorous acid reacts with amine groups on proteins to produce chloramines [28]. 
When HOCl was added to plasma, exogenous UCB inhibited chloramine formation in a dose-
dependent manner. The lowest dose of UCB (versus vehicle treatment) that significantly 
inhibited chloramine formation was 15.6 µM (P<0.05; Figure 1A). Similar results were 
observed on addition of MPO/Cl-/H2O2 system to plasma supplemented with exogenous UCB. 
Significant inhibition of chloramine formation was observed with an additional 12.5 µM 
UCB added to plasma (corrected for plasma dilution factor 1:4), representing the lowest 
effective concentration (P<0.05; Figure 1B). To determine whether UCB directly scavenged 
various model chloramines, albumin-bound UCB was added to biologically relevant 
chloramine species formed on taurine, glycine and N-α-acetyl-lysine. Addition of BSA (250 
µM) in the absence of UCB to an equimolar concentration of each chloramine resulted in 
some quenching (170 – 210 µM) of the chloramines (Figure S1), which approximated the S-
H content of BSA (data not shown). The remaining chloramines (~30-80 µM) were rapidly 
quenched by albumin bound UCB (0-125 µM) in a dose-dependent manner (Figure 2). The 
lowest dose to significantly scavenge chloramine was 3.9-7.8 µM (P<0.05), depending on the 
chloramine species tested. These data indicate that mildly increased exogenous UCB 
concentration (within the physiological range) can protect protein from MPO/HOCl mediated 
chloramine formation by directly quenching biologically relevant chloramine species.  
To confirm whether endogenously elevated UCB would therefore protect from 
chloramine formation, serum/plasma samples from Gunn rats and humans with GS were also 
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challenged, followed by chloramine assessment.  Unconjugated bilirubin concentrations were 
significantly elevated in Gunn rats versus controls (82.3±11.6 vs. 2.55±0.16 µM; P<0.01; 
Figure 3A). Gunn rats have significantly improved antioxidant status (Ferric reducing ability 
of plasma, FRAP; P<0.01; Figure 4A) which was strongly and positively correlated with 
UCB concentrations (r=0.950; P<0.01; Figure S2A). Chloramine formation was inhibited by 
~40% in hyperbilirubinemic Gunn rat serum, compared to control samples (0.20±0.02 vs. 
0.34±0.07 nmols/mg protein; P<0.01; Figure 5A) when exposed to MPO/HOCl oxidation and 
was negatively correlated with UCB concentration (r=-0.840, P<0.001; Figure S3A). A sub-
set of plasma samples from GS subjects with mildly elevated endogenous UCB 
concentrations were obtained from a previous study [33]. Similarly, UCB concentrations 
were significantly elevated in GS compared to controls (34.8±18.5 vs. 10.5±2.87 µM; P<0.01; 
Figure 3B), who tended to experience elevated FRAP concentrations (P=0.095; Figure 4C). 
Serum UCB concentration was significantly correlated with FRAP concentrations in the 
human cohort (r=0.521; P<0.01; Figure S2C). Reduced thiol concentrations were also 
significantly elevated in GS (P=0.002; Figure 4D) and were also positively correlated to 
UCB concentrations (r=0.403; P<0.01; (Figure S2D). Gilbert’s syndrome plasma was also 
protected from MPO-mediated chloramine formation compared to controls (0.09±0.06 vs. 
0.14±0.07 nmols/mg protein; P<0.01; Figure 5B) with chloramine formation being negatively 
correlated with UCB concentrations (r=-0.486, P<0.01; Figure S3B).   
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Figure 1. A) Exogenous UCB inhibits reagent HOCl (100 µM)-mediated chloramine 
formation (0, 15.6, 31.2, 62.5, 125, 250 µM; n=5). B) Exogenous UCB inhibits MPO/H2O2 
(50 µM)-mediated chloramine formation in a concentration-dependent manner (0, 3.125, 6.25, 
12.5, 25, 50 and 100 µM; n=4). *P<0.05, **P<0.001 versus untreated samples (ANOVA; 
Dunn’s post-hoc analysis). 
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Figure 2. Exogenous UCB quenches A) taurine, B) glycine and C) N-α-acetyl lysine 
chloramines (250 µM) in a concentration-dependent manner (0, 3.9, 7.8, 15.6, 31.2, 62.5, 125 
µM; n=3). **P<0.01 versus untreated samples (ANOVA; Dunn’s post-hoc analysis). 
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Figure 3. A) Unconjugated bilirubin concentrations in hyperbilirubinemic in Gunn rats (n=9) 
and littermate controls (n=5) and B) Gilbert’s syndrome and controls (n=21 per group). 
*P<0.01 between the groups. 
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Figure 4. A) FRAP and B) reduced thiol concentrations in hyperbilirubinemic in Gunn rats 
(n=9) and littermate controls (n=5). C) FRAP and D) reduced thiol concentrations in 
Gilbert’s syndrome and controls (n=21 per group). *P<0.05 between the groups.  
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Figure 5. A) MPO-mediated chloramine formation in hyperbilirubinemic in Gunn rats (n=9) 
and littermate controls (n=5) and in B) Gilbert’s syndrome and controls (n=21 per group). 
*P<0.01 between the groups. 
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3.2 Inhibition of protein carbonyl formation by MPO mediated oxidation 
Chloramines decompose to yield protein carbonyls, a stable biomarker of protein 
oxidation and CVD risk [28,40-42]. Formation of protein carbonyl was inhibited in a 
concentration dependent manner with ≥25 µM UCB significantly inhibiting protein oxidation 
(P<0.05; Figure 6A).  
 
3.3 Inhibition of malondialdehyde formation by MPO mediated oxidation 
Oxidative damage to lipids, particularly LDL, is associated with the severity, and 
potentially development of CVD [43,44]. Despite the protective effects of UCB on 
MPO/HOCl-mediated protein oxidation (i.e chloramine and protein carbonyl formation), 
UCB may also inhibit MPO-mediated lipid oxidation (i.e. malondialdehyde; MDA). 
Myeloperoxidase-mediated MDA formation was significantly inhibited in the presence of 
UCB (50-100 µM; P<0.05), the inhibition of which occurred in a concentration-dependent 
manner (Figure 6B). Malondiadehyde and protein carbonyl formation were inhibited 
similarly by exogenous UCB supplementation, as indicated by a positive correlation between 
MDA and protein carbonyl formation mediated by MPO oxidation in the presence of various 
UCB concentrations (Figure 6C).  
. 
 
Unconjugated bilirubin (µM)
0 20 40 60 80 100
Pr
o
te
in
 
ca
rb
o
n
yl
 
(n
m
o
ls/
m
g 
pr
o
te
in
)
0.10
0.15
0.20
0.25
0.30
0.35
0.40
*
* *
Unconjugated bilirubin (µΜ)
0 20 40 60 80 100
M
a
lo
n
di
a
de
hy
de
 
( µµ µµ
M
)
1.0
1.2
1.4
1.6
1.8
2.0
2.2
2.4
*
*
A
B
Protein carbonyl (nmols/mg protein)
0.20 0.22 0.24 0.26 0.28 0.30 0.32 0.34 0.36
M
a
lo
n
di
a
de
hy
de
 
( µµ µµ
M
)
1.4
1.6
1.8
2.0
2.2
2.4C
 
 
Figure 6. A) Exogenous UCB inhibits MPO/H2O2 (100 µM)-mediated protein carbonyl (n=5) 
and B) malondialdehyde (n=3) formation in a concentration-dependent manner (0, 25, 50 and 
100 µM; ANOVA; Dunn’s post-hoc analysis) *P<0.05. C) Correlation between MPO/H2O2 
(100 µM)-mediated protein carbonyl and malondialdehyde formation in plasma 
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supplemented with exogenous UCB (0 µM, ○; 25 µM, ●; 50 µM, ■; 100 µM, ▲; r=0.760; 
P<0.01).  
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4. Discussion 
The present study demonstrates that UCB protects proteins and lipids from MPO 
induced oxidation, which represents an important biological source of oxidants implicated in 
disease pathogenesis [45-47]. Plasma supplemented with UCB reduced HOCl and MPO-
induced chloramine formation. Importantly, albumin-bound UCB directly quenched taurine-, 
glycine- and N-α-acetyl-lysine- chloramines at low micromolar concentrations. Chloramine 
formation, induced by MPO, was also significantly inhibited by UCB in two physiologically 
relevant models of benign hyperbilirubinemia; in serum/plasma from humans with GS and 
Gunn rats. Unconjugated bilirubin further inhibited the formation of chloramine 
decomposition products including protein carbonyl and malondialdehyde, which was likely 
mediated by direct quenching of chloramine by UCB. Therefore, these data provide a 
biologically relevant mechanism to explain protection from protein and lipid oxidation and a 
hypothetical mechanism that may contribute to protection from atherosclerosis observed in 
individuals with mildly elevated UCB concentrations.  
 
Individuals with benign hyperbilirubinemia often possess impaired uridine 
diphosphate-glucuronosyl transferase (UGT1A1) activity [48,49], underpinned by an 
increased TA repeat polymorphism in the UGT1A1 gene promoter, which  contributes to 
elevated UCB levels observed in GS. Epidemiological reports indicate that 
hyperbilirubinemic individuals are protected from atherosclerosis and CVD [1-4,6,12]. 
Bilirubin is an endogenous antioxidant, which efficiently scavenges various oxidant species 
in vitro [14-16,18,50,51]. For example, one molecule of albumin-bound bilirubin efficiently 
inhibits the oxidation of albumin-bound fatty acids by scavenging two peroxyl radicals [16]. 
Unconjugated bilirubin protects against oxidative modification of BSA, lysozyme and 
melittin from radicals induced by irradiation of oxygen [15]. In a similar study, bilirubin also 
. 
 
efficiently inhibited protein carbonyl formation mediated by radiolysis [14]. Nevertheless, 
testing whether UCB resists protein and lipid oxidation generated from biologically relevant 
systems, such as MPO-generated HOCl, in physiologically relevant models of 
hyperbilirubinemia is sparse and of great importance, if we are to understand the potential 
physiological importance of UCB in protecting from disease. 
 
4.1 Reagent HOCl oxidation 
Blood plasma is rich in proteins and amino acids including lysine, tyrosine and 
methionine, which are particularly susceptible to oxidative modification by HOCl [37,52]. 
Treatment of proteins with HOCl induces protein carbonyl formation via the hydrolysis of 
chloramines, which are considered biomarkers of protein oxidation [53,54]. Chloramines also 
decompose via pathways leading to protein side-chain modification, fragmentation and cross-
linking [53]. However, the mechanisms by which UCB, at physiological concentrations, 
might inhibit the formation of these oxidized products in plasma are poorly described. In the 
present study, exogenous UCB (15.6- 250 µM; after correcting for serum dilution) efficiently 
inhibited reagent HOCl (100 µM) induced chloramine formation (measured at 5 min) in a 
concentration dependent manner, with 15.6 µM representing the lowest effective 
concentration. To determine whether bilirubin could directly quench chloramines we 
preformed chloramine on taurine, glycine and N-α-acetyl lysine. These biologically relevant 
chloramines react readily with protein thiols [37] and we show that albumin-bound UCB 
quenched chloramine formation at low micromolar concentrations (ie. 3.9-7.8 µM). These 
observations indicate that bilirubin co-operates with albumin to neutralise HOCl-mediated 
chloramine, which could otherwise decompose and further oxidize proteins and lipids. These 
data suggest that normal physiological UCB concentrations (5-10 µM) could contribute to 
quenching chloramine, and at bilirubin concentrations in GS (≥17.1 µM) may strongly inhibit 
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chloramine formation. We show that 15.6 µM albumin-bound UCB quenched ~47, ~23, ~35 
µM taurine, glycine and lysine chloramine species, suggesting that bilirubin quenches a ~1.5- 
3 molar excess of chloramine, when associated with albumin.  
 
These observations are in general agreement with previous publications showing that 
BRT (≥25 µM), a synthetic water soluble bilirubin analogue, rapidly and efficiently 
scavenged HOCl (100 µM) in a concentration-dependent manner [19]. The authors concluded 
that higher concentrations of bilirubin (conjugated or unconjugated) within pathological 
conditions (eg. liver failure, GS, Dubin-Johnson, Rotor, Crigler-Najjar syndromes or 
conjugated bilirubin in bile) [55,56] may scavenge HOCl in vivo, however, did not test this 
specifically [31]. Interestingly, albumin-bound UCB (~15 µM) did not react efficiently with 
reagent HOCl (50 µM) in vitro [31]. These observations may also have been affected by the 
low concentration of bilirubin and HOCl tested in this in vitro system, the matrix within 
which it was tested (a BSA solution), which did not reflect the composition of human plasma 
or potentially that oxidation products of bilirubin contribute further to neutralising HOCl [19]. 
Despite these limitations, these data indicated that unconjugated bilirubin was unlikely to 
react sufficiently with HOCl to mediate protection from protein oxidation.  
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4.2 MPO-generated HOCl oxidation 
Stocker et al. showed that BRT (10 µM) did not inhibit the MPO-H2O2 mediated oxidation of 
guaiacol; however, showed that the tetraguaiacol product formed from guaiacol oxidised 
BRT [19]. The failure of BRT to inhibit guaiacol oxidation might be influenced by the 
relatively short oxidation period (ie. 5 min) used during testing. Plasma treated with MPO 
induces chloramine formation gradually after 30 mins of incubation [37]. In the present study 
however, the reaction of plasma with MPO for 30 mins resulted in chloramine formation, 
which was dose-dependently inhibited by exogenous UCB (12.5-100 µM). More importantly, 
Gunn rat serum and GS plasma were less susceptible to MPO-induced chloramine formation 
and suggested a dose response effect of UCB. Gunn rats possessed a greater antioxidant 
status (FRAP) versus controls, reflecting the contribution of bilirubin to antioxidant status in 
this assay. Strong, significant correlations between reduced thiols, glutathione and UCB 
concentrations were reported in humans within our previous study [33] and are in agreement 
with elevated circulating sulfhydryl groups reported in another GS cohort [57]. These data 
suggested dose-dependent protection from HOCl oxidation associated with UCB may also be 
influenced by improved antioxidant capacity (ie. reduced thiols), which may reduce 
chloramine formation by providing a kinetically more favourable target for reaction in vivo 
[27]. However, we have demonstrated that albumin-bound UCB efficiently reacts with 
preformed chloramine species, providing a novel mechanism to explain how UCB protects 
from MPO induced oxidation. Investigation of the rate constant for chloramine 
decomposition in the presence of bilirubin would provide important information as to 
whether bilirubin represents a kinetically favourable target for oxidation. However, 
methodological limitations including the need to associate bilirubin with BSA (which 
contains sulfhydryl groups that compete for oxidation) and/or sufficiently sensitive, specific 
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and rapid quantitation of bilirubin currently preclude the accurate quantification of such a rate 
constant. 
 
Plasma-derived chloramines decompose relatively slowly (over 4 hr) resulting in the 
formation of protein carbonyls [29,58]. Myeloperoxidase has previously been implicated as a 
source of protein carbonyls in vivo [59] and reduced protein carbonyl concentrations are 
associated with a decreased risk of CVD events [41,60,61]. Individuals with a greater UCB 
concentrations (≥ 40 µM), have reduced circulating protein carbonyls, which are negatively 
correlated with the UCB concentration in vivo [33]. Our present data shows that exogenous 
UCB supplementation (25-100 µM) effectively inhibited secondary protein carbonyl 
formation mediated by MPO-generated HOCl. Cumulatively, these data provide a 
mechanistic link to explain how endogenously elevated UCB inhibits protein carbonyl 
formation, via the direct quenching of intermediate chloramine formation.   
 
Previous studies have reported that exposure of LDL to reagent HOCl or MPO-generated 
HOCl induces the modification of amino acid residues of apolipoprotein B-100 (apo B) 
associated with LDL, followed by lipid peroxidation [30,43,62-64]. Chloramines give rise to 
nitrogen centred radicals, in turn leading to the generation of secondary radicals [29,53]. 
These radicals derived from chloramine on apo B could initiate lipid peroxidation in LDL 
[30]. However, no data exists to link UCB and inhibition of lipid oxidation mediated by 
MPO-generated HOCl. We show that addition of exogenous UCB (≥50 µM) to plasma 
significantly inhibits MPO-generated MDA formation, a biomarker of lipid oxidation. 
Together these data suggest an important role of UCB in protecting protein and lipid 
oxidation by directly scavenging intermediate chloramines [30,65], which could potentially 
contribute to CVD protection (Figure 7). It should be noted however, such a statement is 
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speculative and that animal models of CVD development (ie. ApoE-/- mice), with 
endogenously elevated and decreased bilirubin would need to be developed to provide a 
conclusive evidence for a role of bilirubin in atheroprotection. 
 
5. Conclusion 
This translational report shows that UCB, at physiologically relevant concentrations, 
protects from protein and lipid induced MPO-generated HOCl oxidation and suggests that 
this inhibition is accompanied by direct scavenging of chloramine by albumin-bound UCB. 
Inhibition of protein oxidation is reported upon exogenous UCB addition to human plasma, 
and within two independent models (rats and humans) of hyperbilirubinemia. These data 
provide a biologically relevant mechanism which could potentially contribute to reducing the 
incidence of CVD in GS. If this hypothesis is confirmed, strategies aimed at modifying haem 
catabolism and bilirubin metabolism, leading to mildly elevated circulating bilirubin, may 
provide a new target for therapy in humans at risk of atherosclerosis [66]. 
 
. 
 
Figure 7. Summary of bilirubin’s protective mechanism, which inhibits MPO/HOCl 
oxidation, and the potential importance of this within the context of atherogenesis. (1) 
Vascular smooth muscle cells stimulate the production of reactive oxygen species (ROS) (eg. 
hydrogen peroxide [H2O2] superoxide [O2-]), which are released into the interstitium. (2) 
Myeloperoxidase (MPO) is abundantly expressed by monocytes/macrophages and produces 
powerful oxidants, hypochlorous acid (HOCl) in the presence of H2O2, hydrogen (H+) and 
chloride ions (Cl-). (3) Hypochlorous acid reacts readily with amino groups on proteins 
including methionine (Met), lysine (Lys), histidine (His) and cysteine (Cys) resulting in 
chloramine formation. (4) Chloramines, carbon (C-) and nitrogen (N-) centred radicals 
derived from chloramine can propagate protein and (5) lipid peroxidation. (6) These radicals 
derived from chloramine can initiate the modification of Apo-B associated with LDL. (7) 
Macrophages express scavenger receptors that bind and endocytose oxidized LDL (oxLDL), 
(8) which can initiate inflammatory responses and augment foam cell formation. Bilirubin 
(UCB) is a potential antioxidant and may directly scavenge intermediate chloramine 
formation, protecting from MPO/HOCl induced protein and lipid oxidation.   
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7. Supplementary figures 
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Figure S1. Remaining chloramine (y-axis) in the presence of BSA (250 µM), 5 mins after the 
addition of 31.2-500 µM (x-axis; A) taurine-, (B) glycine- and (C) N-α-acetyl-lysine-
chloramine. Based upon these results, 250 µM chloramine was selected to test whether 
albumin-bound UCB could quench unreacted chloramine. 
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Figure S2. Correlation between unconjugated bilirubin and A) FRAP (r=0.950; P<0.001) and 
B) reduced thiol (r=0.181; P=0.537) in hyperbilirubinemic in Gunn rats (●; n=9) and 
littermate controls (○; n=5). Correlation between unconjugated bilirubin and C) FRAP 
(r=0.521; P<0.01) and D) reduced thiols (r=0.403; P<0.01) in hyperbilirubinemic in GS (●) 
and control (○) subjects (n=21 per group). 
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Figure S3. Correlation between MPO/H2O2 (50 µM)-induced chloramine formation and 
unconjugated bilirubin concentrations in hyperbilirubinemic A) Gunn rats (●; n=9) and 
littermate controls (○; n=5; r=-0.826, P<0.001) and B) GS (●) and control (○) subjects (n=21 
per group: r=-0.486; P<0.01).  
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Highlights 
• Endogenous hyperbilirubinemia is associated with protection from atherosclerosis 
• Unconjugated bilirubin appears to directly quench biologically relevant chloramines 
• Plasma from hyperbilirubinemic humans and rodents was protected from myeloperoxidase 
generated chloramines 
• Inhibition of chloramine formation in plasma supplemented with bilirubin was associated 
with protection of proteins and lipids from oxidation 
 
 
 
